依普利酮在治疗高血压这方面疗效如何呢？

How effective is eplerenone in treating hypertension? The clinical trial uses losartan as a reference to evaluate the clinical efficacy and safety of eplerenone (Inspra) in the treatment of mild to moderate essential hypertension.

Experimental method: 72 patients with mild to moderate hypertension were selected and randomly divided into: ambulatory blood pressure group, losartan group, and eplerenone (Inspra) group, with 24 cases in each group. The losartan group and the eplerenone group adopted a double-simulation and positive drug parallel control method and received losartan and eplerenone treatment respectively. After 4 weeks of treatment, if the blood pressure did not reach the target, the drug dose was doubled and the treatment continued for 4 weeks; if the blood pressure reached the target, the original dose was maintained and the treatment continued for 4 weeks. The ambulatory blood pressure group took eplerenone 25 mg once a day. 

The results showed that after 8 weeks of treatment, compared with before treatment, the average sitting diastolic blood pressure of the eplerenone group decreased by (13.32±4.57) mmHg, and that of the losartan group decreased by (10.90±5.64) mmHg. The difference between the two groups was not statistically significant. After 8 weeks of treatment, compared with before treatment, the average sitting systolic blood pressure of the eplerenone group decreased by (23.56±9.39) mmHg, and that of the losartan group decreased by (18.67±7.00) mmHg. The difference between the two groups was not statistically significant; the eplerenone (Inspra) group and losartan The average sitting blood pressure compliance rates of the two groups were 83.33% and 91.30%, respectively, with no statistically significant difference between the two groups; the effective rates of blood pressure reduction were 75.0% and 60.9%, respectively, and the total effective rates of blood pressure reduction were 91.7% and 91.3%, respectively. There were no statistically significant differences between the groups in the effective rate of blood pressure reduction and the total effective rate of blood pressure reduction.

At present, Eplerenone (Inspra) has not been launched in China. For detailed price information, you can consult the medical companion travel service.